This study is testing whether guanfacine extended release (GXR), a 3mg tablet taken once daily, can help reduce drinking in people with Alcohol Use Disorder (AUD). Researchers will compare guanfacine to a placebo (an inactive pill) over 12 weeks. They will look at how much participants drink, their blood alcohol levels, and how much they drink after stressful events. You may be able to join if you are 18 or older, identify as the gender you were assigned at birth, have moderate to severe AUD, and want to quit drinking. The study aims to enroll 200 men and women, but its current status is unclear.

Study design

This is an interventional study comparing guanfacine extended release to a placebo in 200 men and women with Alcohol Use Disorder (AUD). Participants will be randomly assigned to receive either the active drug or the placebo.

What's involved

You would take a tablet once daily, with the dose gradually increasing over three weeks and then tapering off over two weeks. You would also provide brief reports throughout the day and evening, have blood alcohol concentration (BAC) levels collected three times daily for 12 weeks, and participate in twice-weekly remote visits.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints, such as changes in drinking days and blood alcohol levels, are measured through week 12 of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.